Association between transforming growth factor-β1 expression and the clinical features of triple negative breast cancer

Ding,Ming-Jian; Su,Ke; Cui,Guo‑Zhong; Yang,Wen‑Hua; Chen,Liang; Yang,Meng; Liu,Yan-Qing; Dai,Dian-Lu

doi:10.3892/ol.2016.4497

Association between transforming growth factor-β1 expression and the clinical features of triple negative breast cancer

Authors:
- Ming-Jian Ding
- Ke Su
- Guo‑Zhong Cui
- Wen‑Hua Yang
- Liang Chen
- Meng Yang
- Yan-Qing Liu
- Dian-Lu Dai
View Affiliations

Affiliations: Department of Oncology, Cangzhou Central Hospital, Cangzhou, Hebei 061000, P.R. China, Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: April 26, 2016 https://doi.org/10.3892/ol.2016.4497
Pages: 4040-4044

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association between the expression levels of transforming growth factor-β1 (TGF-β1) and the clinical pathological characteristics and prognosis of triple negative breast cancer (TNBC) through study of TNBC patient tissue samples. The biological effects of TGF‑β1 on TNBC cells and the potential signal transduction pathway are additoinally investigated. Immunohistochemistry was utilized to investigate expression changes of the positive rate of TGF‑β1 in the TNBC, compared with the non‑TNBC group, to explain the association between TGF‑β1 and clinical pathological characteristics and prognosis. MDA‑MB‑231 cells were treated with TGF‑β1 and subsequently the invasion and migration abilities, and the expression of proteins in certain signaling pathways were assessed before and after the treatment. Positive expression of TGF‑β1 was observed in 52.5% of TNBC tissue samples, which was higher than that observed in non‑TNBC group (27.5%). High levels of TGF‑β1 expression were not significantly associated age, menopausal status, family history of cancer or tumor size; however, tumor histological grade and axillary lymph node metastasis were significantly associated (P<0.05). In addition, when the TGF‑β1 expression levels are higher, the 5‑year disease‑free survival rate is lower. TGF‑β1 expression promoted the invasion and migration of MDA-MB-231 cells, and the expression of Smad2 protein and P38 protein was increased, indicating that Smad2 protein and the P38 signaling pathway may serve an important role in TNBC.

View Figures

View References

1	Kumar P and Aggarwal R: An overview of triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269. 2016. View Article : Google Scholar : PubMed/NCBI
2	Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: Therapeutic options. Lancet Oncol. 8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI
3	Bao P, Peng P, Gu K, Wu C, Huang Z, Gong Y, Zhang M and Zheng Y: Long-term survival analysis of different breast cancer molecular subtypes: Shanghai Breast Cancer Survival Study. Zhonghua Wai Ke Za Zhi. 53:928–934. 2015.(In Chinese). PubMed/NCBI
4	Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Reagan RM, Gabram SG and Eley JW: Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA. Breast Cancer Res Treat. 113:357–370. 2009. View Article : Google Scholar : PubMed/NCBI
5	Marshall J: Transwell(®) invasion assays. Methods Mol Biol. 769:97–110. 2011. View Article : Google Scholar : PubMed/NCBI
6	Bierie B and Moses HL: Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 21:49–59. 2010. View Article : Google Scholar : PubMed/NCBI
7	Padua D and Massagué J: Roles of TGF-beta in metastasis. Cell Res. 19:89–102. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bierie B and Moses HL: Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle. 8:3319–3327. 2009. View Article : Google Scholar : PubMed/NCBI
9	Nagaraj NS and Datta PK: Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 19:77–91. 2010. View Article : Google Scholar : PubMed/NCBI
10	Coban S, Yüksel O, Koçkar MC, Köklü S, Basar O, Tutkak H and Ormeci N: The significance of serum transforming growth factor beta 1 in detecting of gastric and colon cancers. Hepatogastroenterology. 54:1472–1476. 2007.PubMed/NCBI
11	Minamiya Y, Miura M, Hinai Y, Saito H, Ito M, Ono T, Toda H, Motoyama S and Ogawa J: Transforming growth factor-β1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung. Tumour Biol. 31:437–441. 2010. View Article : Google Scholar : PubMed/NCBI
12	Bellam N and Pasche B: Tgf-beta signaling alterations and colon cancer. Cancer Treat Res. 155:85–103. 2010. View Article : Google Scholar : PubMed/NCBI
13	Bao J, Wu ZS, Qi Y, Wu Q and Yang F: Expression of TGF-beta1 and the mechanism of invasiveness and metastasis induced by TGF-beta1 breast cancer. Zhonghua Zhong Liu Za Zhi. 31:679–682. 2009.(In Chinese). PubMed/NCBI
14	Lang DS, Marwitz S, Heilenkötter U, Schumm W, Behrens O, Simon R, Reck M, Vollmer E and Goldmann T: Transforming growth factor-beta signaling leads to uPA/PAI-1 activation and metastasis: A study on human breast cancer tissues. Pathol Oncol Res. 20:727–732. 2014. View Article : Google Scholar : PubMed/NCBI
15	Kajdaniuk D, Marek B, Borgiel-Marek H and Kos-Kudła B: Transforming growth factor-β1 (TGFβ1) in physiology and pathology. Endokrynol Pol. 64:384–396. 2013. View Article : Google Scholar : PubMed/NCBI
16	Heldin CH, Landström M and Moustakas A: Mechanism of TGF-beta signaling to growth arrest, apoptosis and epithelialmesenchymal transition. Curr Opin Cell Biol. 21:166–176. 2009. View Article : Google Scholar : PubMed/NCBI
17	Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, Feng XH, Sawaya R, Medema RH, Hung MC and Huang S: Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis. J Clin Invest. 124:564–579. 2014. View Article : Google Scholar : PubMed/NCBI
18	Taylor MA, Parvani JG and Schiemann WP: The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia. 15:169–190. 2010. View Article : Google Scholar : PubMed/NCBI
19	Shin BA, Yoo HG, Kim HS, Kim MH, Hwang YS, Chay KO, Lee KY, Ahn BW and Jung YD: P38 MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells. Oncol Rep. 10:1467–1471. 2003.PubMed/NCBI